SQUAWK/NEWS
Account
Theme
Account
Menu
Live News REGULATION FLASH L impact

Bio-Thera Says China Approves BAT2306 Secukinumab Biosimilar

China’s National Medical Products Administration approved marketing authorization for Bio-Thera’s BAT2306, the first secukinumab biosimilar approved in China.

Story updates

11:09:20 AM UTC
SquawkNews
Bio-Thera Solutions received NMPA approval for BAT2306, the first secukinumab biosimilar in China, for psoriasis, ankylosing spondylitis and psoriatic arthritis. It will be marketed as 优卓美 (YOUZHUOMEI).Material DetailsContext by AI AnalystThis is a milestone regulatory win expanding Bio-Thera’s bio…

Related stories